Targeted Investigational Therapy Shows Anticancer Activity in Multiple

Targeted Investigational Therapy Shows Anticancer Activity in Multiple Cancer Types.

“Dr. Sequist and colleagues enrolled in their trial 107 patients with a tumor shown to have an FGFR genetic alteration by central or local prescreening. Most patients had squamous cell lung carcinoma or breast cancer, but patients with a variety of other cancers, including cholangiocarcinoma and urothelial cell/bladder cancer, also participated.”

http://www.ascopost.com/ViewNews.aspx?nid=16105

The drug used was BGJ398 –

Thinks this was the trial – http://clinicaltrials.gov/show/NCT01928459